• Products
    • Pritumumab
    • CLNH5
    • MultiPharm
  • Investors
    • Corporate Governance
    • Contact Investor Relations
  • News
  • About
    • Corporate Management
    • Board of Directors
    • Science Advisory Board
  • Contact
Development and delivery of human antibodies for the treatment of cancer Development and delivery of human antibodies for the treatment of cancer Development and delivery of human antibodies for the treatment of cancer
  • Products
    • Pritumumab
    • CLNH5
    • MultiPharm
  • Investors
    • Corporate Governance
    • Contact Investor Relations
  • News
  • About
    • Corporate Management
    • Board of Directors
    • Science Advisory Board
  • Contact

Archives

Monthly Archive for: "October, 2020"
 Nascent Biotech Announces Promising Covid-19 Invitro Study Results with Syracuse University Collaboration
0
By Nascent Biotech
In Corporate News, News, Press Releases, Science News
Posted October 20, 2020

Nascent Biotech Announces Promising Covid-19 Invitro Study Results with Syracuse University Collaboration

SAN DIEGO, CA / ACCESSWIRE / October 20, 2020 / Nascent Biotech, Inc. (OTCQB:NBIO) (“Nascent Biotech” or the “Company”) is pleased to announce that the Company has [...]

READ MORE
 Daily Orange: Professor researches antibody as possible treatment for COVID-19
0
By Nascent Biotech
In Uncategorized
Posted October 14, 2020

Daily Orange: Professor researches antibody as possible treatment for COVID-19

From Syracuse University’s Daily Orange website: A Syracuse University professor is conducting research into a possible treatment to combat coronavirus. Alison Patteson, an assistant [...]

READ MORE
 Nascent Biotech Continues to Reduce Liabilities by Over $2.0 Million Dollars
0
By Nascent Biotech
In Corporate News, News, Press Releases
Posted October 1, 2020

Nascent Biotech Continues to Reduce Liabilities by Over $2.0 Million Dollars

SAN DIEGO, CA / ACCESSWIRE / October 1, 2020 / Nascent Biotech, Inc. (OTCQB:NBIO) Announced today that It has continued to reduce its liabilities through stock conversion and payment of accounts [...]

READ MORE
© NASCENT BIOTECH, INC. ALL RIGHTS RESERVED.